Inovio discloses preliminary cash of $36.7 million as of June 30, 2026
The disclosure came in an 8-K filed alongside a prospectus supplement dated July 29, 2026, with no operating or pipeline updates included.
Inovio Pharmaceuticals filed a Form 8-K on July 29, 2026 reporting a preliminary cash figure, without including any updates on clinical trials, regulatory filings, or pipeline timelines.
As of June 30, 2026, the company estimated its cash and cash equivalents at approximately $36.7 million.1 The company said this figure is preliminary and unaudited, based on management's estimates for the quarter, and cautioned that it is not a comprehensive statement of its financial results as of and for the quarter ended June 30, 2026, and is subject to completion of the Company's financial closing procedures.1
The preliminary data was prepared by and remains the responsibility of company management, and Ernst & Young LLP has not audited, reviewed, examined, compiled, or applied agreed-upon procedures to it, so the auditor does not offer any assurance on the numbers.1
The filing noted that risks regarding the company's business are detailed in its SEC filings, including the risk factors section of a prospectus supplement filed with the SEC on July 29, 2026, its Form 10-Q for the quarter ended March 31, 2026, and its Form 10-K for the year ended December 31, 2025.1
The report was signed by Chief Financial Officer Peter Kies on July 29, 2026.1 No further operational, regulatory, or clinical details were included in this filing.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.